Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4972971 | 0.78 | KCNH2 (0.44) | KCNH2CHRM3ADRA1AOPRK1OPRM1 | |
| SCHEMBL4638235 | 0.72 | KIF11 (0.39) | KCNH2CHRM3ADRA1AOPRK1OPRM1 | |
| SCHEMBL5861679 | 0.71 | KIF11 (0.38) | KCNH2CHRM3ADRA1AOPRK1OPRM1 | |
| SCHEMBL7281996 | 0.67 | HRH1 (0.62) | CNR1KCNH2CHRM3ADRA1AOPRK1 | |
| Hydrochloric Acid SCHEMBL7274257 | 0.65 | HRH1 (0.60) | CNR1KCNH2CHRM3ADRA1AOPRK1 | |
| SCHEMBL10234508 | 0.64 | CYP2C19 (0.46) | KCNH2CHRM3OPRM1CHRM2CHRM1 | |
| SCHEMBL18994323 | 0.64 | OPRM1 (0.64) | KCNH2CHRM3OPRK1OPRM1OPRD1 | |
| SCHEMBL6014665 | 0.64 | OPRM1 (0.64) | KCNH2CHRM3OPRK1OPRM1OPRD1 | |
| SCHEMBL11530 | 0.64 | CYP2D6 (0.40) | KCNH2CHRM3ADRA1AOPRK1OPRM1 | |
| SCHEMBL7374412 | 0.63 | KCNH2 (0.47) | KCNH2CHRM3ADRA1AOPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 545 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| US-20150313846-A1 | PROLONGED-RELEASE MULTIMICROPARTICULATE ORAL PHARMACEUTICAL FORM | FLAMEL IRELAND LIMITED (IE) | 2015-11-05 | — | — | US | claimed |
| US-9023400-B2 | Prolonged-release multimicroparticulate oral pharmaceutical form | FLAMEL TECHNOLOGIES (FR) | 2015-05-05 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8895063-B2 | Oral dosage form comprising an antimisuse system | FLAMEL TECHNOLOGIES (FR) | 2014-11-25 | — | — | US | claimed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140288454-A1 | Method For Using Exhaled Breath to Determine the Presence of Drug | Pulmonary Analytics (US) | 2014-09-25 | — | — | US | claimed |
| US-8652529-B2 | Anti-misuse microparticulate oral pharmaceutical form | FLAMEL TECHNOLOGIES (FR) | 2014-02-18 | — | — | US | claimed |
| US-8445023-B2 | Anti-misuse microparticulate oral pharmaceutical form | FLAMEL TECHNOLOGIES (FR) | 2013-05-21 | — | — | US | claimed |
| WO-2006089843-A2 | ANTI-MISUSE MICROPARTICULATE ORAL DRUG FORM | FLAMEL TECHNOLOGIES (FR) | 2006-08-31 | — | — | WO | claimed |
| EP-1569925-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004055003-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| WO-2004028548-A2 | INHIBITORS OF THE NITRIX OXIDE SYNTHASE III (NOS III) AS NEUROPROTECTIVE AGENTS | CARBOMER, INC. (US) | 2004-04-08 | — | — | WO | claimed |
| US-20040063612-A1 | Neuroprotective agents | CARBOMER, INC. | 2004-04-01 | — | — | US | claimed |
| EP-0608893-B1 | Compositions for inhibiting the development of tolerance to and/or dependence on an additive substance | UNIV VIRGINIA COMMONWEALTH (US) | 2001-12-12 | — | — | EP | claimed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063612-A1 | Neuroprotective agents | GAP43, NLN, NOS3 | CNR1 1532/4885CNR2 1846/4885KCNH2 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.